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By 1980 it was obvious that to more fully understand adaptive immunity, one needed to
somehow reduce the tremendous complexity of antigen recognition byT cell populations.
Thus, there were two developments that resulted in a paradigm shift in immunology, one
being the generation of monoclonal antibodies (MoAbs), and the other the development of
monoclonal functional antigen-speciﬁc T cell lines. For the ﬁrst time, the cellular reagents
became available to ask new questions as to how individual cells comprising the complex
cell populations recognize and respond to changes in their molecular environments. The
ﬁrst successful generation of monoclonal T cells depended upon the understanding that
antigen renders cells responsive to the antigen non-speciﬁcT cell growth factor that came
to be termed interleukin-2 (IL-2), which could then be used in propagating large numbers of
the progeny of single cells, which in turn could then be used for molecular analyses. Mon-
oclonal functional human T cells were used to immunize mice to generate clone-speciﬁc
(clonotypic)MoAbs, which then permitted the ﬁrst biochemical characterizations of the anti-
gen recognition elements of theT cell antigen receptor (TCR) complex. Moreover, the use
of monoclonal cytolytic and helper/inducer humanT cell clones essentially proved that theT
cell-speciﬁcmoleculesT4 (CD4) andT8 (CD8) functioned as accessorymolecules in antigen
recognition by deﬁning MHC class II or class I restriction respectively. As well, the expres-
sion of the T3 (CD3) molecules, found to be common to all T cells, were shown further to
be obligatory for functional antigen-speciﬁcT cell signaling.The monoclonal IL-2-dependent
T cells were also instrumental in the isolation and puriﬁcation of the IL-2 molecule to homo-
geneity, the ﬁrst interleukin molecule to be identiﬁed and characterized. These advances
then led to the generation of pure radiolabeled IL-2 molecules that were used to identify the
ﬁrst interleukin cellular receptors, and as well the generation of the ﬁrst MoAbs reactive
with both IL-2 and IL-2 receptors. All of these advances led subsequently to the isolation of
the ﬁrst cDNA clones recognizing one of the two chains comprising theT cell antigen recog-
nition elements (β-chain), as well cDNA clones encoding IL-2. Accordingly, armed with all
of these unique cellular and molecular reagents, it was possible to determine that antigen
triggering of theTCR complex initiates IL-2 production and IL-2 receptor expression, which in
turn initiate theT cell clonal proliferative expansion, envisioned by Burnet in his formulation
of the clonal selection theory.Thus, adaptive immunity receives antigen-speciﬁc activation
signals from the environment and turns them into antigen non-speciﬁc endogenous action
signals.
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MURINE MONOCLONAL CYTOLYTIC T CELLS
To move beyond descriptive T cell biology, it was necessary to
reduce the tremendous complexity and heterogeneity of T cell
populations to the progeny of a single T cell, so that it would be
possible to fulﬁll Burnet’s prediction that, “Only by the use of a
pure clone technique of tissue culture, which allows mesenchymal
Abbreviations: AFC, antibody forming cell; anti-Tac, MoAb reactive with IL-2Rα
chain; APC, antigen-presenting cell; CATSUP, con-A T cell supernatant; CD, cluster
of differentiation; CTL, cytotoxic T lymphocyte; CTLL, cytotoxic T lymphocyte line;
EBV, Epstein–Barr virus; HPLC, high pressure liquid chromatography; Ia, immune-
associated antigen (MHC class II); IEF, isoelectric focusing; IL, interleukin; LAF,
lymphocyte activating factor (IL-1); LPS, lipopolysaccharide; Ly-CM, lymphocyte
cells to retain full functional activity, would we be likely to ﬁnd
an answer” (to the clonal selection hypothesis; Burnet, 1959).
Thus, following the lead of those who had employed repetitive
alloantigen stimulation to generate long-term cultures of T cells,
Fathman andHengartner (1978) attempted to use repetitivemixed
leukocyte cultures (MLC) to develop T cell clones. Unfortunately,
conditioned media; MLC, mixed leucocyte culture; PBMC, peripheral blood
mononuclear cell; PHA, phytohemagglutinin; RWAGE, ragweed antigen E; SDS-
PAGE, SDS polyacrylamide gel electrophoresis; T3, CD3; T4, CD4; T8, CD8; TCGF,
T cell growth factor; TCR, T cell antigen receptor complex; Ti, clonotypic TCR; TRF,
T cell replacing factor; TSF, T cell stimulatory factor; TT, tetanus toxoid.
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their cultured cells lost their antigen-speciﬁc cytolytic capacities
so that they could not demonstrate clonality. Nabholz et al. (1978)
also tried to generate cytolytic clones of alloreactive cells using
colony formation in soft agar. However, they too could not demon-
strate monoclonal cytolytic function, and both groups had no
way to expand any cells that they had isolated beyond repetitive
MLC.
Because our long-term cytotoxic T lymphocyte lines (CTLL)
had been generated against allogeneic leukemia cells, and had
demonstrable alloantigen cytolytic speciﬁcity as well as syngeneic
tumor-speciﬁc cytolytic speciﬁcity, after 17 weeks of continu-
ous culture in T cell growth factor (TCGF; IL-2) we cloned the
cells using TCGF in liquid suspension culture in microtiter plates
(Baker et al., 1979). We hypothesized that we should obtain some
cloneswith only alloreactivity andotherswith tumor-speciﬁc reac-
tivity. Cells were seeded by limiting dilution at 0.3–0.1 cells/well,
so that by Poisson statistics the probability that wells would be
seeded with more than one cell was <0.05. Remarkably, the calcu-
lated plating efﬁciency ranged from67 to 100%.Of 24 clones tested
for cytolytic activity against allogeneic vs. syngeneic leukemia cells,
10 (42%) speciﬁcally only lysed the allogeneic targets, four clones
(17%) lysed only the syngeneic targets, six clones (25%) lysed both
allogeneic and syngeneic targets, and four (17%)were not cytolytic
for either target. The cytolytic pattern of the clones remained con-
stant over several weeks of culture, and to further prove clonality,
one clone was selected and subcloned: all subclones demonstrated
identical cytolytic activity. This was the ﬁrst report that it was pos-
sible to derive true monoclonal cytolytic T cells. We concluded
that, “detailed studies of the phenotypic and functional characteris-
tics of monospeciﬁc, homogeneous, cytolytic T lymphocytes will now
be possible” (Baker et al., 1979).
Themethods detailed in this ﬁrst paper regarding T cell cloning
(Baker et al., 1979) were rapidly taken up and reproduced by
everyone interested in generating their own antigen-speciﬁc T
cell clones. Noteworthy among one of the ﬁrst conﬁrmatory
reports using our methods to expand and grow large quanti-
ties of clonal progeny, was the creation of a clone cytolytic for
a minor histocompatibility antigen (H-Y) by von Boehmer et al.
(1979). Von Boehmer’s group immunized female mice with male
H-Y+ splenocytes, then activated the female splenocytes by repet-
itive MLC in vitro, followed by growth in soft agar containing
Con-A T cell supernatant (CATSUP) until microscopic colonies
(20–30 cells) could be observed, picked, and expanded in lympho-
cyte conditioned medium (Ly-CM). Thus, the introduction of the
growth-promoting properties of the Ly-CM were critical, in that
they enabled the continuous propagation and expansion of the
progeny so that the cells could be characterized and proved to be
derived from a single cell. Also, when these investigators re-cloned
the original cell line to prove clonality, they used our limiting dilu-
tion method rather than colony formation in soft agar. Limiting
dilution cloning is much simpler and very efﬁcient.
MONOCLONAL ANTIBODIES AND HUMAN T CELL SURFACE
MOLECULES (T3, T4, T8)
The other major advance that occurred during the 1970s was
George Kohler’s and Cesar Milstein’s development of meth-
ods to create somatic cell hybrids (hybridomas) using mouse
plasmacytoma cells and B cells from splenocytes frommice immu-
nized with SRBCs, thereby generating monoclonal antibodies
(MoAbs) with deﬁned antigen speciﬁcity (Kohler and Milstein,
1975). This advance was truly revolutionary, because for the
ﬁrst time hybridomas could be generated and expanded to pro-
duce unlimited quantities of individual antibodies that could
be used for a myriad of research purposes. In particular, the
hybridoma technology brought the study of human immune
responses into the forefront, because it was simple to immu-
nize mice with human cells and molecules to produce speciﬁc
MoAbs, whereas obviously, mouse cells and molecules were not
immunogenic for mice. Not until almost a decade later were
MoAbs raised against murine antigens, by immunizing either
rats or hamsters to produce B cell fusion partners for murine
plasmacytomas.
One of the ﬁrst breakthroughs was fromReinherz et al. (1979b)
who reported the separation of functional subsets of humanT cells
by aMoAb. Using aMoAb designated OKT4 raised against human
peripheral T cells (Kung et al., 1979), Reinherz et al. (1979b)
found that the MoAb reacted with ∼ 60% of peripheral human
T cells, while it was unreactive with human B cells, null cells
and macrophages. Separation of human peripheral T cells into
OKT4+ and OKT4− subsets, followed by testing for prolifera-
tive responses to T cell mitogens and antigens, indicated that
both subsets were responsive to T cell mitogens, but that most
of the proliferative capacity of T cells resided in the OKT4+
population. Even more remarkable, after an MLC, most of the
cytolytic activity was attributable to the OKT4− subset, while the
OKT4+ subset appeared to provide helper activity for cytolytic
T lymphocyte (CTL) generation, as we had shown for TCGF
(Baker et al., 1978). As noted by the authors, the OKT4 MoAb
appeared to recognize the human T cell subset equivalent to that
deﬁned by murine Ly1 alloantisera reported by Kisielow et al.
(1975) and independently by Cantor and Boyse, 1975). Additional
experiments by Reinherz et al. (1979a) afﬁrmed that the OKT4+
subset provided “help” for the generation of antibody forming
cells (AFCs) from human B cells whereas the OKT4− subset did
not. However, the mechanism(s) whereby the helper T cells (Th)
promoted both the generation of CTL and AFCs remained to be
deﬁned.
Monoclonal antibodies that recognized the reciprocal,
cytolytic/suppressor subset, OKT5/8 (subsequently renamed
CD8) was reported soon thereafter by Reinherz et al. (1980b).
This MoAb was found to react with the human homolog of
the murine determinant Ly2, recognized by the murine alloan-
tisera. By using MoAbs, instead of alloantisera, and the new,
very sensitive technique of ﬂow cytometry (Ledbetter et al., 1980),
LeonardHerzenberg’s group found themouse Ly1 alloantigens are
expressed on all T cells to varying amounts, so that a reciprocal
marker for the mouse helper/inducer T cell subset, like human
T4, was lacking. Actually, a MoAb that recognized the murine
homolog of humanT4was only generated 4 years later byDialynas
et al. (1983) working with Frank Fitch and his group.
HUMAN MONOCLONAL CYTOLYTIC T CELLS
In the interval, Reinherz’s group had already derived both T4+ and
T5/8+ human alloreactive cytolytic T cell clones. By stimulating
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peripheral blood mononuclear cells (PBMCs) with an Epstein–
Barr virus (EBV)-transformed B cell line in an MLC, T cell clones
were obtained using both colony formation in soft agar and lim-
iting dilution, followed by expansion in Ly-CM containing TCGF.
They found that the T5/8+ clones were reactive against HLA-A
and B antigens (MHC class I), while the T4+ clones were reactive
against immune-associated (Ia) antigens (MHC class II; Meuer
et al., 1982). Thus, whatever the nature of the T cell antigen recep-
tor (TCR), these cloned T cells speciﬁcally recognized either the
serologically deﬁnedHLA-encodedmolecules or I-region encoded
molecules on the surface of alloantigen-presenting cells, but not
both. It is noteworthy that of ﬁfteen T8+ clones tested, all exhib-
ited a high level of cytotoxicity against the stimulating alloantigen,
while only two of seven T4+ clones tested exhibited cytotoxi-
city. However, it is equally noteworthy that T4+ clones could
become cytolytic, indicating that there was not a strict delin-
eation between the functions of human T4+ vs. T8+ clones, such
as helper vs. cytolytic that had been deﬁned by studying T cell
populations.
Of equal or even greater importance for understanding T
cell antigen recognition was Reinherz’s report that the OKT3
MoAb blocked antigen-induced T cell proliferation (Reinherz
et al., 1980c). By comparison with the T cell subset MoAbs, this
MoAb recognized all peripheral T cells as well as ∼10% of thy-
mocytes with high immunoreactivity by ﬂow cytometry. In this
regard, reminiscent of Peter Nowell’s experiments showing that
glucocorticoids suppressed phytohemagglutinin (PHA)-induced
lymphocyte blastogenesis and mitosis only if added soon after
PHA (Nowell, 1961), OKT3 was only maximally suppressive when
added at the initiation of antigen stimulation. By comparison, sev-
eral otherMoAbs had no suppressive effects whatsoever, including
OKT1, OKT4, OKT5/8, anti-Ia, and anti-beta-2-microglobulin.
Reinherz interpreted their ﬁndings as: “Both the appearance of this
antigen in intrathymic ontogeny and its critical role in T cell func-
tion suggests that the T3 molecule is related to an important antigen
recognition receptor.”
In this regard, it is noteworthy that Reinherz’s group had used
the reciprocal anti-T4 and anti-T5/8 MoAbs, together with anti-
T3 to show that the majority of human thymocytes were positive
for both T4 and T5/8 (i.e., “double positive”), while <10% of thy-
mocytes were T3+, and these cells were only positive for either T4
or T5/8 expression, but not both (i.e., “single positive”; Reinherz
et al., 1980a). It was not until 5 years later that the ﬁrst murine
T3 molecule was identiﬁed (van den Elsen et al., 1985), so that
Reinherz’s ﬁndings were ﬁnally conﬁrmed in the mouse. Of note,
the First International Cluster of Differentiation (CD) Workshop
nomenclature committee was so compelled by the wealth of data
on T3, T4, and T8 that these molecules were named CD3, CD4,
andCD8 accordingly1 (Bernard andBoumsell, 1984). Thesework-
shops were very important, because they allowed investigators to
test their MoAbs to ascertain whether they were reactive with
known CDs or whether new CDs should be designated. Today





While these articles focused on human antigen-speciﬁc recog-
nition by T cells, my team was focused on the antigen non-
speciﬁc nature of the activities of soluble factors involved in the
antigen-speciﬁc adaptive T cell response. When we submitted our
ﬁndings describing the TCGF bioassay (Gillis et al., 1978), one
of the reviewers asked how we could discriminate TCGF from
macrophage-derived lymphocyte activating factor (LAF; Gery and
Waksman, 1972). The LAF bioassay depended upon demonstrat-
ing enhanced proliferative activity of macrophage supernatants on
murine thymocytes activated by PHA and cultured at high density
(107 cells/mL) for several days (Gery et al., 1972). Also, as already
noted, it was well known that puriﬁed T cells were markedly
less responsive to T cell mitogenic lectins than cell popula-
tions containingboth lymphocytes andmacrophages (Oppenheim
et al., 1968). Accordingly, we tested for Con-A-induced TCGF
production by puriﬁed T cells compared with unpuriﬁed spleno-
cytes, and found that TCGF production was reduced by ∼85%,
as determined by the TCGF quantitative assay (Smith, 1980).
Although adherent cells alone produced no detectable TCGF activ-
ity, reconstitution of puriﬁed T cells with small numbers of
adherent cells completely restored TCGF production (Smith et al.,
1980a). By comparison, thymocytes did not produce detectable
TCGF.
These ﬁndings indicated that adherent cells and mature T cells
must somehow cooperate upon mitogenic lectin stimulation to
produce TCGF. Furthermore, they suggested that perhaps the
limiting factor in thymocyte TCGF production was a relative deﬁ-
ciency of adherent cells. However, as shown by Reinherz, only
∼10% of thymocytes were mature, and we found that only the
cortisol-resistant thymocytes, which comprised ∼10% of thy-
mocytes, were capable of producing TCGF (Smith et al., 1979).
Therefore, perhaps the majority of thymocytes, being immature
simply could not produce TCGF. We still could not be sure which
cell type actually produced TCGF, macrophage or mature T cell.
Thus, in collaboration with Joost Oppenheim’s group, we tested
his puriﬁed preparation of human macrophage-derived LAF and
his puriﬁed preparation of human lymphocyte-derived mitogenic
activity, and found that the LAF had no activity in the TCGF assay,
whereas the lymphocyte-derived activity was positive in both the
LAF assay and the TCGF bioassay. Also, our TCGF preparation
scored positively in both the thymocyte LAF assay and the CTLL
TCGF assay. We presented our ﬁndings together at the Second
International LymphokineWorkshop thatwas held inErmatingen,
Switzerland, in May 1979, and for the ﬁrst time it was appreci-
ated by all investigators present that by using the TCGF bioassay
it was possible to discriminate between monocyte/macrophage-
derived LAF and lymphocyte-derived TCGF (Oppenheim et al.,
1980). These ﬁndings electriﬁed the conference and led to many
late night discussions as to how to interpret the fact that LAF and
TCGF were separable, at least functionally.
Even so, it was still unclear as to how LAF could be mito-
genic for thymocytes and puriﬁed T cells, but not mitogenic for
CTLL. Therefore, in additional experiments, we showed that puri-
ﬁed LAF preparations prepared from lipopolysaccharide (LPS)-
induced human PBMCs prompted cloned murine lymphoma
cells to produce TCGF in a LAF-concentration-dependentmanner
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(Smith et al., 1980b). Thus, it appeared that LAF promoted TCGF
production and that both LAF and TCGF comprised “a bimodal
ampliﬁcation system for the T cell immune response.” Moreover,
because LAF was routinely produced from macrophages via stim-
ulation by LPS, a common immunological adjuvant, these data
indicated that this could explain how adjuvants like LPS func-
tioned to markedly amplify immune responses. In still other
experiments in collaboration with Oppenheim and Lawrence
Lachman, using their puriﬁed human and murine LAF prepara-
tions respectively, we conﬁrmed these ﬁndings and extended them
by showing that glucocorticoids inhibited LAF production from
macrophages, and consequently the LAF-induced proliferation of
thymocytes, but did not suppress the TCGF-induced prolifera-
tion of thymocytes (Smith et al., 1980c). All of these data were
included in a review that summarized our progress and proposed
a newmodel for T cell activation that explainedmany of the exper-
imental ﬁndings that had been enigmatic, as shown in Figure 1
(Smith, 1980).
Accordingly, because LAF and TCGF were clearly distinguish-
able functionally by the TCGF assay, and because LAF was
mitogenic for thymocytes and puriﬁed T cells because it enhanced
T cell TCGF production, these data provided the scientiﬁc ratio-
nale for the interleukin nomenclature. Thus, subsequent to the
Ermatingen Workshop, a proposal was circulated and signed by
most of those investigators working in the ﬁeld of antigen non-
speciﬁc T cell proliferation and helper factors. It was proposed that
LAF be renamed interleukin-1 (IL-1) because it worked upstream,
and TCGF be named interleukin-2 (IL-2), because it was down-
stream of LAF activity (Letter, 1979). The term interleukin was
coined to designate that messages were passed between (inter)
leukocytes (leukin). Like the complement ﬁeld, we anticipated
additional interleukins yet to be discovered. Now, in 2012 there
are 37 interleukins, which constitutes the “modern”nomenclature
for these newly discovered hormone-like molecules.
By comparison, identiﬁcation of the molecule(s) responsible
for antigen-speciﬁc helper and suppressor activities ﬁrst described
in the early 1970s (see Toward amolecular understanding of adap-
tive immunity: a chronology – part I) still had not progressed
beyond their original descriptions, i.e., the removal of the activi-
ties by antigen-bound Sepharose and immunoafﬁnity columns of
Ia alloantisera. As chairman of the session on antigen-speciﬁc fac-
tors, Marc Feldmann summarized the lack of progress in deﬁning
the biochemical natures of the various antigen-speciﬁc helper and
suppressor factors at the Second International LymphokineWork-
shop in 1979: “All we can say at this moment is that there is probably
a family of helper and suppressor factors” (Feldmann, 1980).
FIGURE 1 | A model forT cell activation. Depicts the relationship between
macrophage-derived LAF andT cell-derivedTCGF, with the mitogenic activity
of LAF due to its promotion of TCGF production, and the activity of TCGF to
promote the proliferation of both cytolytic and helper T cell subsets,
with suppressor T cell precursors still questionable. Redrawn from
Smith (1980).
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THE FIRST INTERLEUKIN MOLECULE, IL-2
Although the new nomenclature in many ways simpliﬁed soluble
antigen non-speciﬁc mitogenic factors by placing them into two
categories, one macrophage-derived and the other lymphocyte-
derived, the nomenclature was premature, because neither IL-1
nor IL-2 activities had been puriﬁed to homogeneity and ascribed
to single, individual molecules. Thus, by 1980 it was clear to all in
the ﬁeld that the next step was puriﬁcation.
Most investigators chose to attempt to identify and purify
the molecules responsible for murine mitogenic activities (Wat-
son, 1973; Di Sabato et al., 1975; Farrar et al., 1978; Shaw et al.,
1978a,b). An illustrative report by James Watson in collabora-
tion with Lucien Aarden, Jennifer Shaw, and Vermer Paetkau
focused on the puriﬁcation of 200 mL of supernatant from 10
Balb/c spleens (∼109 splenocytes) activated with Con-A for 18 h
in media supplemented with 1% fetal calf serum (FCS; Watson
et al., 1979). After ammonium sulfate precipitation of the pro-
teins, the sample was subjected to molecular gel ﬁltration, ion
exchange chromatography, and isoelectric focusing (IEF). After
each step, fractions were monitored for activity in three distinct
assays; (1) T cell replacing activity for splenocyteAFCs, (2) Con-A-
induced thymocyte mitogenesis-the LAF assay, and (3) induction
of thymocyte alloantigen-speciﬁc CTL. These investigators found
that fractionation of the Ly-CM by these methods yielded results
that indicated “the molecules responsible for biological activity
in each assay system show identical behavior upon gel ﬁltration,
ion-exchange chromatography, and isoelectric focusing” (Watson
et al., 1979).
By gel ﬁltration, the activities corresponded in size tomolecules
from 30 to 40 kDa, and when applied to an ion-exchange column
eluted with a salt gradient from 0.05 to 0.5 M ammonium acetate
(pH 7.6), with identical activities in both the thymocyte LAF and
AFC assays. By comparison, when monitored by IEF, there was
considerable heterogeneity in pI in the broad range of pH 4–5.
As already mentioned, both macrophage-derived mitogenic fac-
tors (i.e., LAF) and putative T cell-derived mitogenic factors (i.e.,
TCGF, Thymocyte stimulating factor, TSF, T cell replacing factor,
TRF) could not be discriminated by these bioassays. Because the
target cells used, i.e., thymocytes and splenocytes, were hetero-
geneous, when fractions of Ly-CM derived from heterogeneous
producer cells containing both macrophages and lymphocytes
(and both B cells and T cells), it was impossible to dissect the
contributions of one cell and molecule vs. another, and whether
the target cells of a given activity in turn released an additional
activity that was actually detected by the assay. Thus, it was truly
GIGO (garbage in, garbage out).
Also, the Ly-CM was produced in media containing 1% FCS.
Accordingly, it is important to calculate that 1% = 1 g pro-
tein/dL = 10 mg/mL of FCS proteins in the Ly-CM. These
investigators estimated that their cytokine activities were present
in the Ly-CM at concentrations ∼10−9 M, which at molecular
sizes of ∼35 kDa = 35 ng/mL. Therefore, the cytokine activities
were produced inmedia with amillion-fold excess of FCS proteins
vs. cytokine proteins. In fact, as we were to learn subsequently,
TCGF is active at concentrations in the pg/mL range, so that by
using 1% FCS to make the Ly-CM, the FCS proteins were actually
a billion-fold in excess of the cytokine proteins. This made the
puriﬁcation of the FCS proteins away from the cytokine proteins
essentially impossible. Also, because the cytokine protein(s) were
present in inﬁnitesimal amounts, it meant that to be successful,
one needed to begin with very large quantities of Ly-CM. If the
cytokine was present at 150 pg/mL = 10 pM, then 200 mL of
Ly-CM contained only 30 ng of cytokine protein. This was def-
initely not enough to quantify using any of the available protein
assays, such as the colorimetric Bradford assay, which requires
>1 μg protein (Bradford, 1976). Accordingly, even given 100%
recovery of starting material, one would need to start with at least
7 L of Ly-CM, which would equate to 350 mouse spleens, not
just 10.
By comparison with these efforts, we elected to focus on the
puriﬁcation and characterization of molecules with human TCGF
activity. Having solved the problem of target cell heterogeneity by
using murine CTLL clones, we could be conﬁdent that any effects
observed were mediated by direct interaction of the lymphokine
with the target T cells themselves. We decided to focus on human
TCGF because ultimately we hoped to raise a murine MoAb reac-
tive to themolecule(s), and because eventually we hoped to be able
to use TCGF in the clinic. Others at the time favored the notion
that a family of molecules would prove to have TCGF activity,
based on the broad elution proﬁles from the molecular sieve and
ion exchange columns and also from the multiple peaks observed
after IEF. If true, when the molecules were separated, the activity
discernable in the bioassay would be lost.
To approach the problem of serum proteins contaminating
TCGF, we developed a system to produce TCGF in serum-free
media from human PBMCs. To increase the amounts of start-
ing material, we switched to human tonsil lymphocytes, because
we could obtain ∼109 cells from each tonsil, which was equal to
the number of lymphocytes in a liter of blood. Thus, it was pos-
sible to generate 1 L of PHA-induced Ly-CM from each tonsil,
culturing the cells at 1 × 106 cells/mL. Several liters of Ly-CM
were pooled and concentrated >1,000-fold by ﬁltration, then
puriﬁed successively by gel ﬁltration, IEF, and polyacrylamide gel
electrophoresis (PAGE). We were able to show that the hetero-
geneity of charge that others had found examiningmurine Ly-CM
could be eliminated by removal of sialic acid and by the inhibi-
tion of glycosylation. Thus, we could show that TCGF activity
could be ascribed to a molecule with a single charge (pI = 8.2)
and size (14–16,000 Mr), and that all of the apparent molecu-
lar heterogeneity was attributable to variable glycosylation and
not due to multiple protein molecules with TCGF activity (Robb
and Smith, 1981). Thus, for the ﬁrst time, all of the TCGF bio-
logical activity could be ascribed to a single variably glycosylated
protein.
THE TCGF (IL-2) RECEPTOR
Having thus reduced the apparent molecular heterogeneity of
TCGF activity to a single molecule, and knowing the biochem-
ical characteristics of TCGF, i.e., it’s size and pI, we produced
biosynthetically radiolabeled TCGF by culturing cells with amino
acids taggedwith radioisotopes, and then puriﬁed the radiolabeled
TCGF using gel ﬁltration and IEF, until we had a single radi-
olabeled band on SDS-PAGE detectable by ﬂuorography (Robb
et al., 1981). By monitoring the TCGF activity using the bioassay,
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and by measuring the protein concentration of unlabeled puri-
ﬁed TCGF by amino acid analysis and dye binding, we were able
to assign our preparations a speciﬁc activity, i.e., U/μg protein,
and knowing the molecular size (15.5 kDa) we could calculate the
molar concentration of both labeled and unlabeled TCGF (i.e.,
CPM/pmol). Thus, for the ﬁrst time, we could determine that
TCGF was active in the pM range. Ultimately, repeated determi-
nations yielded a dose–response in the range of 1–100 pMwith an
EC50 = 5–10 pM.
Because our radiolabeled TCGF preparations were homo-
geneous and contained no other radiolabeled molecules, we
proceeded with classical radiolabeled ligand-binding assays (Robb
et al., 1981). Kinetic and equilibrium binding experiments
revealed that unstimulated human PBMCs had detectable binding
sites, on the order of ∼200 sites/cell (lower limit of detection = 60
sites/cell), but that upon activation, either with mitogenic lectins
or alloantigens, the number of detectable binding sites increased
remarkably, ∼50-fold, to ∼10,000 sites/cell. Upon plotting the
equilibrium binding data of human radiolabeled TCGF to human
cells by the method of Scatchard (1949), we found a single class of
high afﬁnity binding sites, with an equilibrium dissociation con-
stant (Kd)∼5–10 pM,whereasmurine activated T cells andCTLL,
the Kd was ∼20 pM. Of utmost importance, the concentrations
of radiolabeled TCGF that bound to cells, and the concen-
trations of unlabeled TCGF that promoted T cell proliferation
(EC50 = 1 U/mL = 5 pM) were essentially identical. More-
over, when several other growth factors and lymphokines were
tested, only TCGF successfully competed for radiolabeled TCGF
binding.
Soon after the publication of these data, I was contacted
by Thomas Waldmann. Takashi Uchiyama from his group had
raised a MoAb that only reacted with a human leukemia cell
line that had been used for immunization of mice to produce
hybridomas (Uchiyama et al., 1981a,b). They speculated that their
MoAb might recognize the TCGF receptor, since it did not react
with normal resting T cells, but did react after the T cells were
activated viamitogenic lectins or alloantigens. The very ﬁrst exper-
iments were deﬁnitive, in that the MoAb, subsequently called
anti-Tac (for activated T cell), competed for radiolabeled TCGF
binding in a concentration-dependent manner (Leonard et al.,
1982). Also, anti-Tac precipitated a single glycoprotein of ∼55
kDa from radiolabeled cell surface molecules. Accordingly, these
experiments described the ﬁrst MoAb reactive with an interleukin
receptor.
These ﬁndings were very signiﬁcant, because for the ﬁrst time
they indicated that the immune system, like all other systems in
the body, is under endogenous control via hormone molecules.
Hormones and receptors had already been classically deﬁned by
physiologists in the late nineteenth century (Langley, 1878) and
early twentieth century (Langley, 1905), as substances secreted
by cells that act to elicit a characteristic physiological response at
very low concentrations via interaction with high afﬁnity with a
cellular receptor. Thus, TCGF had all of the characteristics of a
bona ﬁde hormone, including stereospeciﬁcity, high afﬁnity, and a
ﬁnite number of binding sites that are consequently saturable.
Prior to these ﬁndings, the immune system was viewed as
regulated entirely from without via environmental molecules
(antigens), that when introduced were recognized by speciﬁc anti-
gen receptors, which led to the proliferation and differentiation of
the cells which then cleared the antigens. Thus, it was taught that
the immune system was distinct and special, set apart from every
other organ system, and was only aroused and regulated from a
quiescent state by external forces, much like the nervous system
senses changes in the environment, e.g., temperature, light, sound
etc. Therefore, it was thought that once the system cleared the
offending antigen, if there was no longer a driving external force,
it returned to quiescence. Consequently, this dogma was over-
turned by ﬁnding that antigen-speciﬁc T cell clonal expansion is
regulated by an endogenous hormone-receptor system like all of
the other organ systems. It remained true that the introduction of
antigen activates the immune system, but after antigen recognition
there is an endogenous endocrine-like molecular mechanism that
drives the proliferation and differentiation of the cells that actually
mediate the antigen clearance.
The concept that an endocrine mechanism is responsible for
immunoregulation, instead of solely being antigen-regulated, nec-
essarily invoked a way to turn off the IL-2/IL-2R interaction.
Of course, logic dictated that clearance of the antigen should
result in the removal of the TCR-directed signals that control
the expression of IL-2 and its receptors. However, to be termed
a true hormonal system, endocrinologists required evidence for
a hormone-induced negative feedback regulation of either hor-
mone production or receptor expression, or both. Accordingly,
these questions would require additional time and experimental
approaches.
THE MOLECULAR NATURE OF THE TCR COMPLEX
Having developed and propagated IL-2-dependent human T4+
and T8+ cytolytic T cell clones, Reinherz was in a unique position
to identify the molecules responsible for T cell antigen recogni-
tion. Thus, in a seminal report, Reinherz and his group cracked
the enigma of the molecular nature of the antigen recognition
components of the TCR, and revealed the entire TCR complex
for the ﬁrst time (Meuer et al., 1983c). Operating under Burnet’s
clonal selection theory of immunity, which led to the hypothesis
that “there must exist discriminative surface recognition structures
that are unique to individual antigen-responsive T cell clones,”
Reinherz’s group used one of their T8+ cytolytic T cell clones
to immunize mice to produce murine hybridomas, and devel-
oped a screening strategy to select for clone-speciﬁc (clonotypic)
MoAbs.
It was ﬁrst important to determine whether the surface struc-
tures that the clone-speciﬁc MoAbs identiﬁed were actually
involved in antigen recognition. Two such MoAbs were found
to block both the speciﬁc cytotoxic function and antigen-induced
proliferation of the immunizing T8+ T cell clone. Also notewor-
thy, the MoAbs enhanced the proliferation of the T cell clone in
response to IL-2. Moreover, the surface molecules deﬁned by the
MoAbs were linked to the T3 structure, but in contrast to T3
(Mr ∼20 kDa), they precipitated two associated glycoproteins of
apparent molecular weights of 49 and 43 kDa. Reinherz and his
group interpreted their results in an understated, more British,
than American fashion: “It is likely that the clonotypic MoAbs
deﬁne variable regions of the human T cell antigen receptor (on the
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T cell clone) because they recognize clonotypic structures and inhibit
antigen-speciﬁc function.”
Subsequently, to determine whether analogous receptor
molecules could be found on other T cell clones of differing anti-
gen speciﬁcity,MoAbswere generated against a T4+ cytolytic T cell
clone (Meuer et al., 1983a). Three MoAbs from ∼600 hybridomas
were selected, cloned and recloned by limiting dilution. Analysis
of the molecular nature of the T4+ clone surface molecules rec-
ognized by all three antibodies yielded a 90 kDa molecule under
non-reducing conditions, and two distinct bands, a ∼51 kDa α-
chain and 43 kDa β-chain under reducing conditions, thus very
similar to the chains observed on the T8+ T cell clone. Also, in a
fashion similar to the effects of the T8+ clone-speciﬁc MoAbs, the
T4+ cytolytic clone-reactive MoAbs blocked alloantigen-speciﬁc
cytolysis, as well as proliferation, and enhanced IL-2 induced pro-
liferation. These ﬁndings supported the conclusions;“that the basic
subunit composition of the antigen receptors on cells derived from
both the T4+ and T8+ human T cell subpopulations is similar. In
contrast, recognition of class II or class I alloantigens by these subsets
may be determined by the associative recognition structures T4 or T8,
which are independent from Ti/T3.” Also, “the wide distribution of
the 20/25 kDa T3 glycoprotein and the ability of anti-T3 antibodies
to inhibit antigen speciﬁc function of all clones suggest that T3 is a
constant portion of the antigen receptor complex.”
Consistent with this view, the Reinherz group also derived a
series of T4+ clones reactive with speciﬁc protein antigens, rag-
weed antigen E (RWAGE), and tetanus toxoid (TT; Meuer et al.,
1983b). Incubation of these clones with speciﬁc antigen together
with autologous APCs and B cells resulted in the production of
IgG. These T cell clones demonstrated a clear restriction for autol-
ogous class II MHC molecules. Immunization with one of the
RAGWE-speciﬁc clones yielded one clonotypic MoAb from ∼500
hybridomas. Biochemical analysis of immunoprecipitates showed
a similar 90 kDa protein under non-reducing conditions and 52
and 41 kDa under reducing conditions, along with the associated
T3 20/25 kDa molecules.
Accordingly, for the ﬁrst time Reinherz revealed for everyone
the complete TCR complex utilized by both T cell subsets to rec-
ognize and react with antigen. Also, using both ﬂow cytometry
and radiolabeled quantitative clone-speciﬁc MoAb binding anal-
ysis, they found that both the clonotypic (Ti) and T3 structures
to be expressed at a similar level on the cell surface, ∼30–40,000
molecules/cell, whereas the density of T4 and T8 expressed by
the clones was ∼120,000–175,000 binding sites/cell, a 3–6-fold
excess (Meuer et al., 1983a). Other experiments showed that rest-
ing, freshly isolatedT cells had equivalent densities of all three TCR
complex structures, so that antigen or IL-2 activation was specu-
lated to induce the enhanced levels of the accessory molecules T4
and T8.
Because T3 and clone-speciﬁc (Ti) structures appeared to be
associated as they were expressed in equivalent densities and
were co-modulated by their respective MoAbs, additional stud-
ies were performed to further explore this apparent non-covalent
interaction. Having multiple T cell clones available, cell sur-
face radiolabeled molecules could be immunoprecipitated with
anti-T3 and analyzed by SDS-PAGE under reducing conditions
(Reinherz et al., 1983a). In addition to T3 molecules of 20 and
25 kDa, two larger bands of ∼ 49 and 43 kDa were observed
from all clones tested. Also, two-dimensional SDS-PAGE analysis
of the molecules precipitated with anti-T3 revealed two iden-
tical molecules with distinct pIs from the 25 kDa molecules
and ﬁve distinct pIs from the 20 kDa molecules from all of
the T cell clones tested, both T4+ and T8+, thereby conﬁrm-
ing their invariant nature. By comparison, the 43 kDa molecules
co-precipitated by anti-CD3 showed considerable variability by
pI analysis, suggesting peptide heterogeneity. Peptide maps con-
ﬁrmed this heterogeneity of the 43 kDa β-chain molecules from
several clones, and in addition, some variability of the 49 kDa α-
chain molecules was suggested, consistent with the view that these
chains could participate in antigen recognition.
The Reinherz group then reasoned that if the clone-speciﬁc
MoAbs actually recognized the antigen-binding chains of the TCR,
they might also mimic antigen, and activate the T cell clones,
provided they were presented on a solid support (Meuer et al.,
1983d). Thus, individual clone-speciﬁcMoAbs were conjugated to
Sepharose beads. As controls, anti-T3, anti-T4, and anti-T8MoAbs
were also conjugated to Sepharose. When tested for their capacity
to induce IL-2 production and proliferation as monitored by 3H-
TdR the results were clear-cut. Only anti-T3 and the appropriate
anti-Ti induced both IL-2 production and proliferation of both T4
and T8 cytolytic clones. Moreover, only soluble anti-T3 and the
appropriate anti-Tiwere capable of inhibiting IL-2 production and
proliferation induced by the solid-phase MoAbs. Subsequently,
they repeated these experiments using helper/inducer T4+ clones
speciﬁc for soluble protein antigens, with identical results (Meuer
et al., 1983b). As concludedby theReinherz team,“these results pro-
vide compelling evidence to support the notion that anti-Ti antibodies
deﬁne the antigen (recognition) receptor structure on individual
clones.”
They also pointed out that the T4 and T8 surface structures,
although critical for MHC-restricted CTL effector function, were
unnecessary for solid-phase MoAb-induced IL-2 production and
clonal proliferation. Their results also indicated that endogenous
IL-2 production was inseparable from clonal proliferation, and
it was clear that a single cell could, under physiological condi-
tions, both produce and respond to its own IL-2. Accordingly,
the molecules involved in antigen recognition and response in
adaptive immunity were thus resolved and revealed.
Additional experiments focused on the biochemical characteri-
zation of the α-chains and β-chains reactive with the clone-speciﬁc
MoAbs showed that the α subunits were more acidic than the β
subunits by IEF, and more importantly, two-dimensional peptide
maps indicated that the β-chains precipitated from two distinct
clones were unique, but did share two peptides in common (Acuto
et al., 1983b). By comparison, a similar analysis of α subunits from
different clones were more related, but not identical. Therefore,
both subunits appeared to contain both constant and variable
domains, similar to antibodies.
Accordingly, these initial molecular characterizations indicated
some similarities between the αβ antigen recognition elements of
the TCR and antibodies. However, there the similarities ended, in
that an invariant component like T3 involved in signaling had not
been found to be associated with surface immunoglobulin on B
cells. Also, B cells did not express accessory molecules similar to
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T4 and T8 as did T cells. Moreover, the data accumulated by Rein-
herz’s group indicated that restriction of T cell antigen recognition
to MHC class I or class II correlated with the expression of T8 or
T4 respectively. Also, it was noteworthy that the T8/class I and
T4/class II interaction did not necessarily dictate T cell function
of cytolysis vs. help, since T4/class II-restricted T cell clones could
obviously kill appropriate target cells. Finally, all of these data indi-
cated that only one 90 kDa heterodimeric TCR antigen receptor
could recognize alloantigens, and only one receptor could rec-
ognize foreign protein antigens, such as RWAGE and TT + MHC
encodedmolecules simultaneously. All of these ﬁndingswere sum-
marized in January, 1983 (Reinherz et al., 1983b) as shown in
Figure 2.
A few months before Reinherz’s ﬁrst report on the molecu-
lar nature of the entire TCR complex (Meuer et al., 1983c), Allison
et al. (1982) reported that they had generated aMoAb reactivewith
a surface antigen of a T cell lymphoma. Their data indicated that
“the MoAb was highly speciﬁc for the T lymphoma cells used for the
immunizations, and did not react with a panel of other spontaneous
or X-ray-induced or chemically-induced lymphomas.” Of interest,
onbiochemical analysis of surface radiolabeledproteins, theMoAb
precipitated “a glycoprotein composed of disulﬁde bonded subunits
of 39,000 and 41,000 m.w.” In addition, Allison’s group used a
technique of “diagonal” two-dimensional gel electrophoresis com-
bining an SDS-PAGE under non-reducing conditions followed
by re-electrophoresis under reducing conditions. Because most
surface molecules are not disulﬁde linked, most of the proteins
migrate on a diagonal under these conditions. However, the disul-
ﬁde linked proteins reactive with the MoAb migrated off of the
diagonal, because when reduced, the two chains separated into
their lower sizes.
Operating under the hypothesis that the tumor-speciﬁc anti-
gen recognized by their MoAbmight be part of a surface molecule
normally expressed speciﬁcally by T cells, the Allison group
subjected several different types of cells to two-dimensional non-
reducing/reducing SDS-PAGE. They found that puriﬁed T cells
and thymocytes had proteins migrating off of the diagonal in
positions very similar to the MoAb immunoprecipitated proteins
from the T cell lymphoma. By comparison, bone marrow cells
(mostly myeloid and erythroid precursors) and B cells did not
express detectable proteins migrating in this manner. The Alli-
son team speculated that their MoAb might recognize the “T cell
equivalent of the B cell idiotype,” but because they had raised
their MoAb against a tumor cell, they had no way to test for
antigen recognition or immunological reactivity, in contrast to
Reinherz, who had used normal functional IL-2-dependent T cell
clones.
Then, a few months after Reinherz’s ﬁrst seminal report,
another group led by Philippa Marrack reported the generation
of a MoAb reactive with an antigen-speciﬁc murine somatic T cell
hybrid that they had produced by fusing immune Balb/c spleno-
cytes with an azaguanine-resistant thymoma cell line (Haskins
et al., 1983). This “T cell hybridoma,” DO-11.10, was selected
for its capacity to produce IL-2 when stimulated with speciﬁc
antigen, chicken ovalbumin (cOVA), in the presence of APCs
of the appropriate MHC type. Then, splenocytes from a DO-
11.10-immunized mouse were used to make a B cell hybridoma,
which was screened for the capacity to inhibit the production of
IL-2 by cOVA-stimulated T cell hybrids. Supernatants from one
cloned hybridoma, KJ1-26, was selected for study. The KJ1-26
MoAb-containing supernatants selectively inhibited IL-2 produc-
tion only from the immunizing T cell hybridoma, and not from
six other antigen-speciﬁc T cell hybridomas. In addition, this
MoAb speciﬁcally inhibited binding of the DO-11.10 hybridoma
to antigen-pulsed APCs, suggesting that the KJ1-26 MoAb might
recognize a surface structure that bound antigen.
Identiﬁcation of the molecules reactive with the KJ1-26 MoAb
revealed that it immunoprecipitated a molecule of ∼ 80–90 kDa
by SDS-PAGE under non-reducing conditions and two molecules
of 40–44 kDa under reducing conditions. Similar to the Alli-
son group’s experiments using “diagonal” non-reducing/reducing
SDS-PAGE, the KJ1-26 immunoprecipitates revealed a spot that
was below thediagonal, consistentwith it’s disulﬁde-bonded struc-
ture. Accordingly, like the Allison group, the Marrack group had
FIGURE 2 | Model of the humanT cell receptor. EachT lymphocyte displays
two recognition units on its surface: theTi-T3 complex and the associative
recognition structure, T8 or T4. TheT8 andT4 glycoproteins bind
to non-polymorphic regions of class I and class II MHC gene products
respectively. Note that the precise domains of class I and class II that the
T cells recognize are unknown and assigned in the ﬁgure only for purposes of
illustration. TheTi molecules, unique to eachT cell recognize speciﬁc antigen
in the context of a polymorphic MHC gene product, while theT3 molecules,
common to all mature T cells, are involved in signaling the cell interior.
Redrawn from Reinherz et al. (1983b).
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generated a MoAb that reacted with an antigen of similar bio-
chemical characteristics expressed by a T cell hybridoma, and in
addition, they had data showing that the MoAb blocked antigen-
speciﬁc MHC-restricted IL-2 production. However, neither the
Allison nor the Marrack groups had data revealing any other T
cell functions such as proliferation or cytolysis, as they were deal-
ing with cells that proliferated autonomously. Also, there were
no data regarding the T3 signaling components of the TCR com-
plex, nor the nature of the MHC restricting structures T4 and T8.
Their reports on the biochemical characteristics of the putative
antigen recognition elements in these mouse lymphoma cells and
hybridoma cells thus conﬁrmed Reinherz’s ﬁndings regarding the
antigen recognition elements of the humanTCRcomplex, but they
did not describe the entire murine TCR complex on both T4-class
II restricted and T8-class I-restricted T cell clones of both cytolytic
as well as inducer/helper functional phenotypes, as had Reinherz’s
reports.
Once the data from all three groups became known to one
another, they cooperated in their next reports, which were pub-
lished simultaneously in the same journal. The Reinherz group
reported the generation of an additional MoAb reactive with a
human T cell leukemia/lymphoma cell line, which was T3+, T4+,
and T8+ (Acuto et al., 1983a). Three MoAbs that reacted specif-
ically only with this T cell tumor were selected for study. These
MoAbs resembled the clone-speciﬁc MoAbs raised against the
normal T cell clones, in that they did not react with normal
T cells, B cells, macrophages, granulocytes, or RBCs. Moreover,
each of these tumor-speciﬁc MoAbs co-modulated clone-speciﬁc
surface structures, as well as T3, but did not change the surface
expression of T4, T8, or T11. SDS-PAGE analysis of immuno-
precipitates under non-reducing conditions revealed a single
band at 94 kDa, and two bands under reducing conditions (53
and 44 kDa). Peptide maps of the putative α and β-chains
showed that they were distinct molecules, and that they both
shared peptide fragments in common with chains immunopre-
cipitated from normal T cell clones, thereby indicating that all
of the clonotypic MoAbs precipitated chains that shared at least
one peptide fragment, presumed constant domains, as well as
clone-speciﬁc peptides, presumed variable domains. Also, using
“diagonal” two-dimensional SDS-PAGE the Reinherz group sub-
stantiated their earlier reports regarding the T cell phenotype
during thymic maturation (Reinherz et al., 1980a; Reinherz and
Schlossman, 1980) by showing that the clone-speciﬁc TCR recog-
nition molecules appear during intrathymic ontogeny in parallel
with surface T3 expression, so that cells pass from triple nega-
tive (T3−T4−T8−) to double positive (T3−T4+T8+), to T3/Ti+
and single positive for either T4 or T8. Thus, the clonotypic
antigen recognition elements are intimately linked to T3 expres-
sion during ontogeny, thereby providing a structural basis for
the group’s previously reported observation that immunological
competence is acquired only among the population of thymo-
cytes that express surface T3 (Umiel et al., 1982). In this regard,
it is noteworthy that only this very minor subset of thymocytes
(<10%), which also are cortisone resistant, were found respon-
sive to LAF (IL-1), and thus capable of inducing proliferation in
the LAF (IL-1) thymocyte bioassay because they could produce
TCGF (IL-2).
The Marrack group reported data on a second MoAb, this one
reactive with a T cell hybridoma that produced IL-2 in response to
a class I alloantigen (Kappler et al., 1983), their ﬁrst MoAb being
speciﬁc for a T cell hybrid reactive with anMHC class II-restricted
cOVA antigen. This new MoAb, designated KJ12-98, suppressed
IL-2 production by the class I-stimulated T cell hybrid, and in
addition, when bound to Sepharose beads, stimulated IL-2 pro-
duction, as Reinherz had shown for his clone-speciﬁc MoAbs.
Also, similar to all of the previous reports this MoAb precipi-
tated a disulﬁde linked heterodimer, ∼85 kDa, which resolved
into two subunits of 40–43 kDa. Subsequently, Samelson et al.
(1983) reported two MoAbs reactive with a class II-restricted T
cell hybridoma that responded to a pigeon cytochrome C peptide
by producing IL-2. Like the MoAbs of the Marrack group, these
MoAbs inhibited clone-speciﬁc antigen-induced IL-2 production,
and precipitated disulﬁde-linked dimers comprised of 45–50 kDa
molecules.
By comparison, McIntyre and Allison (1983) used their MoAb
to isolate the reactive antigen from their T cell lymphoma cell
line, which they then used to immunize a rabbit to generate
a polyclonal antiserum. This antiserum precipitated disulﬁde-
linkeddimers frombothnormal thymocytes andperipheral T cells,
but not non-T cells. Peptide maps indicated that the molecules
from the different cell sources shared common subunits, as well
as having non-homologous peptide fragments. However, they
still did not have data indicating that either their MoAb or
their antiserum reacted with a structure capable of recognizing
antigens.
Accordingly, by the close of 1983 the enigmatic TCR complex
had been revealed to all in the immunological community. From
the chronology of the reports that appeared during this year, it is
clear that the Reinherz group was ﬁrst, complete and correct, as
time would prove. By comparison, those working in the mouse
necessarily followed Reinherz’s lead, thereby partially conﬁrming
his ﬁndings, but because they lacked identiﬁcation of murine T3
and T4, they could not describe all of molecules of the entire
TCR complex, and consequently they could not trace the expres-
sion of the recognition, accessory, or signaling elements during
T cell ontogeny as did Reinherz. Moreover, because they chose
to work with continuously proliferating T cell lymphomas and
hybridomas instead of using normal IL-2-dependent T cell clones,
they could not examine the function of the TCR complex in T
cell activation, proliferation and any differentiated function such
as cytolysis, beyond showing that their MoAbs interfered with
antigen-induced IL-2 production.
THE IL-2 cDNA, IL-2 GENE, IL-2 MoAbs, AND PURE
HOMOGENEOUS IL-2
The year 1983 was also an important year for IL-2. Tadatsugu
Taniguchi’s group took advantage of the rapid, speciﬁc and quan-
titative IL-2 bioassay to identify a cDNA encoding human IL-2
activity (Taniguchi et al., 1983). mRNA was isolated from the
JURKAT human T leukemia cell line that had been found to
produce IL-2 upon mitogenic lectin stimulation (Kaplan et al.,
1975; Gillis and Watson, 1980). Using methods of hybrid selec-
tion of mRNA and translation in Xenopus laevis oocytes, followed
by assay for TCGF activity using the CTLL-2 cells, a cDNA
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was identiﬁed that possessed TCGF activity. The cDNA speci-
ﬁed 153 amino acids and a 20 amino acid hydrophobic leader
signal sequence so that the mature secreted protein contained
133 residues, yielding a calculated molecular size of 15,420.5 Da,
almost identical to the molecular size we estimated by SDS-PAGE
of both native and radiolabeled TCGF (IL-2; Robb et al., 1981;
Robb and Smith, 1981). Once the cDNA encoding IL-2 had been
identiﬁed, both Taniguchi, as well as ourselves, isolated genomic
clones encoding the entire IL-2 gene (Fugita et al., 1983; Holbrook
et al., 1984). The IL-2 gene spans 8 kb and is organized into four
exons.
Although these genetic studies were informative as to the pri-
mary structure of the IL-2 molecule, and would eventually permit
studies on the TCR complex regulation of IL-2 gene expression,
they did not immediately lead to the availability of large amounts
of pure IL-2 for additional biochemical, biological, and immuno-
logical studies. However, we had developed severalMoAbs reactive
with IL-2, which we used as immunoabsorbants to purify mil-
ligram quantities of homogeneous IL-2 protein (Smith et al.,
1983). Analysis of immunoafﬁnity puriﬁed IL-2 indicated that
it eluted as a single peak from a reverse-phase high pressure liquid
chromatography (HPLC), and migrated as a single size (15.5 kDa)
on silver stained SDS-PAGE. Proof that there were no other con-
taminating proteins in the immunoafﬁnity puriﬁed preparations
was obtained by N-terminal amino acid sequence analysis, which
identiﬁed a single N-terminus, and the ﬁrst 15 residues. Because
this amino acid sequence was identical to that predicted from
the IL-2 cDNA nucleotide base sequence, the data indicated agree-
ment between the predicted cDNAand actual amino acid sequence
analysis, and thus proving that a single molecule mediated IL-2
biological activity.
In addition to proving useful for the immunoafﬁnity puriﬁca-
tion of IL-2, the IL-2 MoAbs effectively neutralized both human
and murine IL-2 activity, but were non-reactive with rat-derived
IL-2. In addition, the neutralization of IL-2 could be competitively
antagonized by an excess of IL-2. Moreover, the concentrations of
IL-2 MoAbs that neutralized IL-2 in a 24 h bioassay were identical
to the MoAb concentrations that block radiolabeled IL-2 equilib-
rium binding, which came to steady state within 15 min. These
experimental results essentially proved that the MoAb neutraliz-
ing capacity depended upon IL-2 binding by the MoAbs, and not
due to non-speciﬁc interference with cellular metabolism in the
bioassay, a problem that hadmisled other investigators attempting
to generate IL-2-speciﬁc MoAbs (Gillis and Henney, 1981; Stadler
et al., 1982).
Additional experiments exploring the immunoafﬁnity adsorp-
tion characteristics of four distinct IL-2 MoAbs indicated that
the single most important parameter is the association rate, and
the temperature-dependence of both the association and disso-
ciation rates (Budd and Smith, 1986b). Thus, as the association
rate increases directly with temperature, we found that the most
efﬁcient immunoafﬁnity adsorption occurred at 37◦C, while the
washing and elution steps were best performed at 4◦C. Moreover,
the efﬁciency of immunoafﬁnity adsorption of separate MoAbs
varied according to their association rates. We also used the IL-2
MoAbs to create the ﬁrst immunoassay for an interleukin (Budd
and Smith, 1986a). For these experiments radiolabeled IL-2 and
radiolabeled IL-2 MoAbs were used to determine the reaction
kinetics at each stage of the immunoassay. Noteworthy was the
ﬁnding that reaction rates are retarded remarkably when per-
formed in the solid-phase vs. solution, and are more rapid at
37◦C than either 20◦C or 4◦C. These advances were paradigmatic
for the uses of MoAbs raised against all of the interleukins that
followed.
cDNA CLONES ENCODING T CELL-SPECIFIC MEMBRANE
PROTEINS
All of the data accumulated by Reinherz on the molecular nature
of the TCR complex indicated that human T cells expressed sur-
face molecules distinct from B cells that were involved in antigen
recognition, as well as the T3 signaling molecules and the T4 and
T8 accessorymolecules associated withMHC restriction. The data
accumulated on the αβ antigen recognition chains indicated that
they were of a different size compared with heavy and light chains
of antibodies, but like antibodies, the TCR chains did appear to
have both constant and variable regions.
Thus, TakMak’s group took these data into consideration to
search for the elusive TCR antigen recognition molecules (Yanagi
et al., 1984). They screened for cDNA clones of mRNAs that were
expressed either exclusively or preferentially in T cells, in contrast
with others who had searched for Ig molecules on both B cells
and T cells (Binz and Wigzell, 1975). Given the T cell-speciﬁc
expression of T3, T4, and T8, they constructed a cDNA library
frommRNA extracted from the human leukemia cell lineMOLT3,
which they found to express T3, T4, and T8 (Nagasawa and Mak,
1982). Of 10,000 cDNA clones screened by differential hybridiza-
tion to mRNA from MOLT3 cells vs. a human B cell lymphoma,
four were selected for further study, which were found to identify
a single mRNA of 1.3 kb by northern blot analysis from MOLT3
that was not detected in the B cell line. Of several human leukemia
cell lines screened, only T cell leukemias were positive, as well as
normal human thymocytes and peripheral T cells, together with a
mouse T cell leukemia cell line.
Todetermine the size of the protein encodedby their cDNA they
used hybrid selection with mRNA from MOLT3 cells, followed by
in vitro translation and analysis by SDS-PAGE, which yielded a
single protein of ∼30 kDa. The nucleotide sequence of one of the
cDNA clones revealed a long open-reading frame that predicted a
34,938 kDa protein, two possible sites for N-linked glycosylation, a
hydrophobic leader sequence at the N-terminus, and a hydropho-
bic region near the C-terminus resembling a membrane anchor.
In addition, the predicted protein resembled human and murine
Ig light chains, especially in the relative locations of the cysteine
residues, as well as extensive homology over the entire length of the
Ig variable, joining and constant regions. These results were very
tantalizing, but there was no way to test for antigen recognition or
any other function because theywere dealingwith lymphoma cells.
Moreover, even if this represented the cDNA encoding an antigen
recognition component of the TCR complex, it represented only
one of the two chains. Thus, the Mak group could only conclude
that, “The nature and function of this protein are unknown; it may
be similar to the knownT cell-speciﬁc antigens (T3, T4, T8), or to the
α- or β-subunits of the recently identiﬁed T-cell receptors” (Yanagi
et al., 1984).
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Following this report, in the same journal issue Hedrick et al.
(1984a) reported their work on a presumptive murine TCR anti-
gen recognition structure. Also operating from a hypothesis that
the T cell antigen recognition elements should be speciﬁcally
expressed by T cells and not by B cells, this team crafted a strat-
egy of constructing 32P-labeled cDNAs of the membrane-bound
polysomalRNA fraction ofmurine antigen-speciﬁcT cell hybrido-
mas, previously described by Samelson et al. (1983), assuming
that mRNAs encoding a membrane molecule would be found
on membrane-bound polysomes. They then subtracted these
cDNAs by an excess of RNAs from B cell polysomes, to ren-
der the radiolabeled cDNA probes T cell-speciﬁc. T cell cDNA
homologous to B cell RNA was removed by fractionation on
hydroxyapatite, which binds double-stranded nucleotides. The
resulting B cell-subtracted 32P-cDNA was used to probe a cDNA
library constructed with mRNA from another B cell subtracted
T cell cDNA preparation. From 5,000 clones screened, 30 were
selected and used for further study. Seven clones hybridized with
mRNA considered large enough to code for a TCR recognition ele-
ment. They next hypothesized that the TCR recognition elements
should undergo genetic rearrangements to create the diversity of
antigen recognition in a manner similar to Ig genes. Thus, they
constructed probes from each of the seven clones and hybridized
them in Southern blots with genomic DNA from liver cells from
the mouse strains used and genomic DNA from the parent T
cell lymphoma used to construct the T cell hybridomas, as well
as genomic DNA from the antigen-speciﬁc T cell hybridoma.
Only one clone of the seven was consistent with DNA rear-
rangements, which were found only in the T cell lymphoma and
hybridomas.
The nucleotide sequence of their longest cDNA clone predicted
a leader sequence of 19 residues, a 98 residue regionwith similarity
tomurine Ig variable regions, a 16 amino acid J region, followed by
a constant-like region, also similar to murine Ig constant regions.
The similarity in sequence between the predicted T cell cDNA
and Ig was so pronounced that it was conjectured that it could
conceivably explain the reported cross-reactivity of B cell anti-
idiotypic antisera with T cells (Binz and Wigzell, 1975). Finally,
there was a predicted hydrophobic membrane-spanning region
near the C-terminus. Thus, the authors concluded that “it must
almost certainly play a part in antigen recognition by T cells.” In
support of this contention, they cited unpublished work which
indicated that antisera raised against peptide fragments predicted
by their cDNA clone signiﬁcantly inhibited the antigen-dependent
release of IL-2 by antigen-stimulated T cell hybridomas (Hedrick
et al., 1984b).
Another way to approach the primary sequence of a TCR anti-
gen recognition molecule was to purify the α and/or β-chains and
performN-terminal amino acid sequence analysis. Thus, the Rein-
herz group chose to use their clone-speciﬁc MoAbs reactive with
their REX T-leukemia cell line because they could grow the requi-
site number of cells more easily than their IL-2-dependent T cell
clones. Lysates from 5 × 1010 cells were immunoafﬁnity puriﬁed
using their clonotypic MoAb. Focusing on the smaller β-chain
(∼ 41–44 kDa), 20–50 μg of protein could be obtained from
∼ 5 × 1010 cells. N-terminal sequencing reproducibly yielded
the ﬁrst 12 residues, minus the ﬁrst amino acid. Comparison of
this sequence with other proteins in the data base yielded a weak
homology with a human Ig λ V-region.
The Reinherz report (Acuto et al., 1984) was submitted for pub-
lication just 3 days before the cDNA sequences were reported.
Thus, Reinherz added a note in galley proof:
“Additional NH2-terminal sequencing of Ti β subunit has iden-
tiﬁed amino acid residues 12, 14, and 16-20 and thus yields
the following sequence: X-Val-Ile-Gln-Ser-Pro-Arg-His-Glu-Val-
Thr-Glu-X-Gly-X-Glu-Val-Thr-Leu-Arg. These 17 amino acids are
identical to 17 residues within the predicted protein sequence of the
YT35 cDNA clone deﬁned by Yanagi et al. (1984). . . . . . . . . . . . . In
addition, the high degree of nucleotide homology between the 3′ end
of the YT35 human cDNA clone and murine cDNA clones (Hedrick
et al., 1984b). . . . . . suggests that the mouse equivalent of the Ti β
gene has (also) been isolated” (Acuto et al., 1984).
Thus, by two different methods, protein and nucleotide
sequencing, the primary structure of the ﬁrst TCR complex
antigen recognition chain became known. In addition, the two
methods validated one another.
TURNING ANTIGEN-SPECIFIC ACTIVATION INTO ANTIGEN
NON-SPECIFIC ACTION
From all of these data, it appeared that although triggering of
the TCR complex initiates T cell proliferative clonal expansion,
there was a heretofore-unknownmolecular mechanism that actu-
ally mediated the complex intracellular biochemical reactions that
perform the necessary molecular events that culminate in DNA
replication and cytokinesis. In this regard, one of the puzzling
aspects of T cell proliferation after mitogenic or antigenic stim-
ulation was the transient nature of the proliferative response. As
noted by Nowell (1960), after the addition of a mitogenic lectin
such as PHA, there ensues an initial lag of 48–72 h, then a rapid
burst of proliferation, followed by a gradual cessation of prolifer-
ative activity and ultimately a cessation of proliferation. Once it
was appreciated that the TCR complex is responsible for IL-2 pro-
duction, and as well, once it became possible to monitor the TCR
complex induction of IL-2R expression, these critical parameters
regulating the T cell proliferative response could be examined. It
appeared that the TCR complex per se could not promote DNA
replication and cytokinesis.
From our initial studies of IL-2 production after mitogenic
lectin triggering, we already knew that there was a burst of IL-2
secretion by the activated cells, followed by a gradual cessation
of IL-2 release, and the disappearance of detectable IL-2 con-
centrations over the succeeding several days (Gillis et al., 1978).
Therefore, this phenomenon alone could explain the transience
of the proliferative response. However, once it became possible
to monitor IL-2R expression, both quantitatively with the radiola-
beled IL-2 binding assay, and qualitatively by ﬂow cytometry using
the IL-2R MoAb, Cantrell and Smith (1983) performed a series
of experiments on the biological importance of IL-2R expres-
sion. Using IL-2 renderedhomogeneous byMoAb immunoafﬁnity
puriﬁcation, biosynthetically radiolabeled IL-2 also immunoafﬁn-
ity puriﬁed with the IL-2-reactive MoAbs, and IL-2R-reactive
MoAbs, the growth characteristics of PHA-activated T cells were
determined and correlated with IL-2R expression for the ﬁrst
time. IL-2Rs appear asynchronously in lectin-activated human
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peripheral T cell populations and precede the onset of DNA
synthesis monitored by 3H-TdR incorporation, as well as by pro-
pidium iodide (PI) quantitative DNA staining and ﬂow cytometry.
Moreover, upon removal of the activating lectin at the peak of
IL-2R expression after 72 h of culture, IL-2R levels do not per-
sist. Rather, a time-related and IL-2 independent decay of IL-2Rs
occurs that is rapidly reversible by re-stimulation with lectin. As
IL-2R appearance and disappearance is mirrored and followed by
the proliferative rate of the cells within the population, our results
indicated that the lectin-induced IL-2R densities were of primary
importance, along with adequate IL-2 concentrations, in deter-
mining the extent of T cell clonal expansion, and consequently by
extrapolation, the tempo,magnitude, anddurationof the resultant
T cell immune response (Cantrell and Smith, 1983).
Although these studies were deﬁnitive with regard to IL-2 and
IL-2Rs, because we had performed the experiments using a mito-
genic lectin as the activating signal, we could not be sure whether
they represented the true physiology of the adaptive T cell immune
response. Thus, it was a natural extension of these studies for us
to collaborate with Ellis Reinherz’s group, once he had established
normal human T cell clones, and had generated clone-speciﬁc
MoAbs. Accordingly, combining Reinherz’s unique cellular and
molecular TCR complex reagents with our unique IL-2 and IL-2R
molecular reagents, for the ﬁrst time it was possible to perform
reductionist science on the molecular nature of the T cell adaptive
immune response, thereby moving from the micrometer to the
nanometer level in immunology (Meuer et al., 1984).
To investigate the relationship between the TCR complex
and IL-2-mediated T cell growth, we used three antigen-speciﬁc
human T cell clones and a series of clone-speciﬁc MoAbs in
conjunction with homogeneous immunoafﬁnity-puriﬁed human
IL-2, as well as MoAbs reactive with both IL-2 and the IL-2R. First,
we established that two human cytolytic T cell clones (T4+ and
T8+), and a protein antigen-speciﬁc helper/inducer T4+ clone,
proliferated in vitro in response to homogeneous puriﬁed IL-2,
thus consistent with our studies that the active ingredient in Ly-
CM was actually IL-2. Second, this IL-2-dependent proliferative
response was essentially completely abrogated by the IL-2RMoAb,
and was reduced from 67 to 75% by the neutralizing IL-2-reactive
MoAb. In contrast, MoAbs reactive with the constant portion of
the human Ia antigen (MHC class II), that like the IL-2R appears
on activated humanT cells, did not diminish IL-2-mediated clonal
proliferation (Meuer et al., 1984).
As observed previously with Ly-CM containing IL-2, we found
that activation using soluble clone-speciﬁc MoAbs enhanced by
2–3-fold 3H-TdR incorporation of each clone in response to
pure homogeneous IL-2. As with IL-2 alone, this increased 3H-
TdR incorporation initiated by the anti-clonotype MoAbs was
completely abrogated by the IL-2R-reactive MoAb and reduced
by two-third by the MoAb that could neutralize IL-2. Since
anti-clonotypic MoAbs did not promote proliferation without
exogenous IL-2, we surmised that the soluble MoAbs may trigger
the expression of IL-2Rs, but not IL-2 production. This hypoth-
esis was tested by ﬂow cytometry. The expression of IL-2Rs was
found to be stimulated sixfold by stimulation with anti-clonotypic
MoAb, and as well, by speciﬁc antigen + APCs. Accordingly, these
data conﬁrmed and extended our previous results using PHA, to
the physiologic reagents of anti-clonotypic MoAb, and speciﬁc
Ag + APCs.
Further experiments comparing activation with soluble vs.
solid-phase anti-clonotypic MoAbs, and either cellular alloanti-
gens or Ag + APCs, showed that soluble anti-clonotypic MoAbs
promoted IL-2R expression but not IL-2 production, whereas the
same anti-clonotypicMoAbs bound to Sepharose beads promoted
both the expression of IL-2Rs and IL-2 production, as did both
alloantigens and Ag + APCs. Thus, “The present construct clearly
implies that T cell proliferation ismediated through an autocrine net-
work in which antigen-receptor triggering leads to IL-2 production,
IL-2R expression, IL-2 release, and subsequent IL-2R occupancy,
which ultimately promotes cell division” (Meuer et al., 1984), as
depicted in Figure 3.
During the course of these experiments, we noted that IL-2R
expression after TCR complex activation occurred asynchronously
among the individual cells within a T cell population. More-
over, examination at the single cell level using the cytoﬂuorograph
and IL-2R MoAbs, a broad range of IL-2Rs/cell was observed,
spanning as much as three orders of magnitude. Accordingly, we
wondered whether differences in IL-2R density made any differ-
ence to the IL-2-dependent proliferative response. In this regard,
a purview of the literature revealed that all cells, both prokary-
otes as well as eukaryotes, proliferate asynchronously, with some
cells proliferating faster than others, even among cloned cell
populations. Thus, we wondered whether this universal charac-
teristic pattern of cell growth could be related to the density of
growth factor receptors as well as the concentration of the growth
factor.
For the ﬁrst time in any cell system, we had accumulated the
necessary molecular and cellular reagents to explore this funda-
mental aspect of cellular proliferation. Of utmost importance, a T
cell population could be synchronized into the G0–G1 phase of the
cell cycle by removal of IL-2, and then maximal levels of IL-2Rs
could be induced by re-stimulation with mitogenic lectins. Upon
exposure to IL-2, the kinetics of IL-2-dependent cell cycle progres-
sion could then be followed and analyzed in relationship to IL-2R
density and distribution among the cells within the population
(Cantrell and Smith, 1984).
When the density of IL-2Rs is monitored by the cytoﬂuoro-
graph with IL-2R MoAbs, and plotted on a log10 scale, like all
surfacemolecules, a log-normal distribution of IL-2Rs is observed.
Since the proportion of occupied receptors is dependent on the
IL-2 concentration, with a log-normal distribution of IL2Rs/cell,
at any given IL-2 concentration the absolute number of occu-
pied IL-2Rs should vary according to the receptor density of each
cell. It follows that if the number of occupied IL-2Rs is criti-
cal for the decision to replicate DNA, a G0–G1−synchronized cell
population with a log-normal distribution of IL-2Rs would be
expected to enter the proliferative phases of the cell cycle asyn-
chronously, as a function of the IL-2 concentration, which was
readily observed. The IL-2 concentration-dependency was most
easily discerned by selecting a single time interval after the addi-
tion of IL-2: a typical sigmoid log-dose–response curve resulted
whether the response was monitored by 3H-TdR incorporation
or PI staining, which indicated that the magnitude of 3H-TdR
incorporation reﬂected the proportion of cells that had left G0–G1
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FIGURE 3 | Schematic model ofT cell proliferation mediated
by an IL-2-dependent autocrine mechanism. Stage 1: resting T cells
or T cell clones express few or no IL-2 receptors, while reciprocally
displaying a maximal number of antigen receptors (V). Stage 2: T3-Ti
triggering by antigen/MHC-restricting element or surface bound anti-T
cell receptor antibodies results in T3-Ti modulation, thus reducing the
number of surface antigen receptors and rapidly inducing surface IL-2
receptor expression. Stage 3: This event appears to occur prior to IL-2
secretion itself because IL-2 receptor expression can be observed 2–4 h
after T3-Ti triggering, whereas IL-2 is not detectable in culture supernatants
until at least 10–12 h later. Stage 3 can also be achieved with anti-Ti or
anti-T3 monoclonal antibodies in soluble form. Stage 4: activation via Ti-T3
leads to production and secretion of endogenous IL-2 (•) and subsequent
binding to its own IL-2 receptors. Stage 5 : once a critical density of
occupied IL-2 receptors is achieved, DNA synthesis and mitosis occur.
Finally, in the absence of additional antigenic stimulation, there is
re-expression of the surfaceT3-Ti complex (stage 1). Redrawn from Meuer
et al. (1984).
and entered the proliferative phases of the cell cycle (Cantrell and
Smith, 1984).
In other experiments, the duration of the IL-2/IL-2R interac-
tionwas found to be a critical determinant of cell cycle progression,
so that there appeared to be an interplay between at least two
variables, IL-2 concentration and the duration of the IL-2/IL-2R
interaction, such that the number of cells responsive to a subop-
timal IL-2 concentration could be increased by lengthening the
exposure period. These observations suggested that the absolute
number of IL-2/IL-2R interactions occurring during the G1 phase
of the cell cycle was critical for the decision of a cell to divide.
A series of experiments varying the IL-2 concentration, the IL-2R
density or the duration that these twomolecules interacted proved
this hypothesis, and for the ﬁrst time showed that cellular division
is a deterministic and not a probabilistic phenomenon. Moreover,
the decision is quite simple and depends upon only four vari-
ables: (1) the afﬁnity of the IL-2/IL-2 interaction, which dictates
(2) the IL-2 concentrations necessary to saturate the IL-2Rs, but
(3) the IL-2R density/cell and (4) the duration of the IL-2/IL-2R
interaction are equally important (Cantrell and Smith, 1984).
CONCLUSION
In just 5 years, the understanding of adaptive immunity under-
went a sea-change, from a science focused on populations of cells
to one focused on individual cells and molecules for the ﬁrst time.
No longer was the TCR complex, both structurally and function-
ally, an enigma. Gone were the notions that T cells recognized
antigens via Ig molecules, although the antigen recognition struc-
tureswere found tobemembers of what came tobe knownas the Ig
superfamily. Moreover, the TCR complex became deﬁned as com-
prised of antigen recognition structures of α- and β-chains, as well
as accessory molecules, T4 and T8, that facilitated recognition of
antigens “in the context” of MHC-encoded molecules, and which
were found to be intimately involved in T cell ontogeny. Moreover,
the TCR complex included the T3 signalingmolecules, which were
expressed by all T cells. Also gone were antigen-speciﬁc factors, as
T cells were not found to secrete their antigen recognition struc-
tures, as do B cells. Moreover, the MHC-encoded molecules also
were shownnot to beTCRs, andnot to be secreted as helper or sup-
pressor “factors.” Rather, the genetic control of the T cell immune
response was found to be involved with antigen presentation via
MHC-encoded molecules, which T cells recognize via only one
receptor, not two. In addition, T cells were found to mediate their
antigen-speciﬁc responses via signaling the expression of antigen
non-speciﬁc molecules, the cytokines or interleukins, and their
receptors. Consequently, the immune response could no longer
be considered a unique, passive system that only functioned in
response to external signals from the environment. Like all of
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the other bodily systems, the immune system became appreciated
for the ﬁrst time to be regulated by endogenous hormone-like
molecules via speciﬁc hormone-like receptors. These changes in
our perception of how the adaptive immune system is structured
and how it functions led immediately to a new vista of exper-
imental possibilities, one where the exploration of a myriad of
new molecules and biochemical signaling pathways have made
immunology one of the most interesting and rapidly expanding
areas of biology, and onewhere it is now on its way to contribute in
amajor way to twenty-ﬁrst centurymedicine. Moreover, to launch
this quest, the torch was passed to a new generation of immu-
nologists armed with cloned cells, cloned antibodies and cloned
genes, techniques that were transformative for the new science of
molecular immunology.
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